Literature DB >> 15141945

Nucleotide substitutions in Staphylococcus aureus strains, Mu50, Mu3, and N315.

Toshiko Ohta1, Hideki Hirakawa, Kazuya Morikawa, Atsushi Maruyama, Yumiko Inose, Atsushi Yamashita, Kenshiro Oshima, Makoto Kuroda, Masahira Hattori, Keiichi Hiramatsu, Satoru Kuhara, Hideo Hayashi.   

Abstract

A specific phenotype of Staphylococcus aureus strains Mu50 and Mu3 is characterized by thickened cell wall and moderate resistance to vancomycin. The N315 strain is a prototype of methicillin-resistant S. aureus (MRSA), but it is methicillin susceptible, despite carrying the mecA resistance gene. Here, we revised differences in the sequences of Mu50 and N315, referencing that of Mu3 which were assumed to be of one lineage. The 362 ORFs diverse between Mu50 and N315 were picked up, and the corresponding ones in three strains were re-sequenced. This defined 213 ORFs diverse between Mu50 and N315, and 9 between Mu50 and Mu3. The fixed diversities of 174 ORFs (except for 39 silent ORFs from 213), including nucleotide substitution (NSs), frame shift, and truncation were grouped into three major functional categories, which were transport (14.9% in the 174 diverse ORFs), metabolism of carbohydrates (5.7%), and RNA synthesis (9.6%). The other gene categories had small diversities. These gene categories seemed to be functionally decisive for the Mu50-specific characters, the thickened cell wall and moderate vancomycin resistance. All of the diverse genes and the high quality sequence of Mu50 can be viewed at the web site (http://133.5.48.239/VRSA/).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15141945     DOI: 10.1093/dnares/11.1.51

Source DB:  PubMed          Journal:  DNA Res        ISSN: 1340-2838            Impact factor:   4.458


  21 in total

1.  The effects of iclaprim on exotoxin production in methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.

Authors:  Amy E Bryant; Sumiko Gomi; Eva Katahira; David B Huang; Dennis L Stevens
Journal:  J Med Microbiol       Date:  2019-01-24       Impact factor: 2.472

2.  DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus.

Authors:  Longzhu Cui; Jian-Qi Lian; Hui-Min Neoh; Ethel Reyes; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression.

Authors:  Christopher R E McEvoy; Brian Tsuji; Wei Gao; Torsten Seemann; Jessica L Porter; Kenneth Doig; Dung Ngo; Benjamin P Howden; Timothy P Stinear
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

4.  walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.

Authors:  Mitsutaka Shoji; Longzhu Cui; Risa Iizuka; Akira Komoto; Hui-min Neoh; Yukiko Watanabe; Tomomi Hishinuma; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

5.  Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach.

Authors:  Adrien Fischer; Soo-Jin Yang; Arnold S Bayer; Ali R Vaezzadeh; Sébastien Herzig; Ludwig Stenz; Myriam Girard; George Sakoulas; Alexander Scherl; Michael R Yeaman; Richard A Proctor; Jacques Schrenzel; Patrice François
Journal:  J Antimicrob Chemother       Date:  2011-05-28       Impact factor: 5.790

6.  Cloning, expression, purification and characterization of UMP kinase from Staphylococcus aureus.

Authors:  O Hari Prasad; Y Nanda Kumar; O V S Reddy; Abhijit Chaudhary; P V G K Sarma
Journal:  Protein J       Date:  2012-04       Impact factor: 2.371

Review 7.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

8.  Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.

Authors:  Michael M Mwangi; Shang Wei Wu; Yanjiao Zhou; Krzysztof Sieradzki; Herminia de Lencastre; Paul Richardson; David Bruce; Edward Rubin; Eugene Myers; Eric D Siggia; Alexander Tomasz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-21       Impact factor: 11.205

9.  A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin.

Authors:  Karla D Passalacqua; Sarah W Satola; Emily K Crispell; Timothy D Read
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

10.  Effect of genetic background on the evolution of Vancomycin-Intermediate Staphylococcus aureus (VISA).

Authors:  Michelle Su; Michelle H Davis; Jessica Peterson; Claudia Solis-Lemus; Sarah W Satola; Timothy D Read
Journal:  PeerJ       Date:  2021-07-13       Impact factor: 3.061

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.